Impact of a program encouraging the use of generic antipsychotics

American Journal of Managed Care

Volumn 18, Issue 8, 2012, Pages

  Hermes, Eric D A ^a   Sernyak, Michael ^b   Rosenheck, Robert ^a,c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

^c VA New England Mental Illness   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; GENERIC DRUG; OLANZAPINE; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; HEALTH SURVEY; HUMAN; MENTAL DISEASE; MOOD DISORDER; OUTCOME ASSESSMENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SLEEP; TOTAL QUALITY MANAGEMENT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DRUGS, GENERIC; HEALTH CARE SURVEYS; HUMANS; MIDDLE AGED; MOTIVATION; PHYSICIAN'S PRACTICE PATTERNS; QUALITY IMPROVEMENT; STATISTICS, NONPARAMETRIC;

EID: 84869204902     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Sernyak MJ, Rosenheck RA. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr Serv. 2008;59(5):567-569.
2. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-1376.
3. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA. 2003;290(20):2693-2702.
4. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
6. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6): 553-564.
7. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361(9369):1581-1589.
8. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
9. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomized trial. Br J Psychiatry. 2008;193(4): 279-288.
10. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105(1-3):175-187.
11. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156 (11):1686-1696.
12. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv. 2008;59(5):507-514.
13. Comer JS, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry. 2011;168(10):1057-1065.
14. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatr Serv. 2009;60(9):1175-1181.
15. BCC Research. Antipsychotic drugs: technologies and global markets. Report PHM063A. BCC Research Market Forecasting. http://www .bccresearch.com/ report/antipsychotic-drugs-markets-phm063a.html.Published June 2010. Accessed January 15, 2011.
16. Duggan M. Do new prescription drugs pay for themselves: the case of second-generation antipsychotics. J Health Econ. 2005;24(1):1-31.
17. Red Book. Montvale, NJ: Thomson Reuters; 2010.
18. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research. JAMA. 2003;289(4):454-465.
19. Montgomery JH, Byerly M, Carmody T, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials. 2004;25(6):598-612.
20. Arbuckle MR, Gameroff MJ, Marcus SC, West JC, Wilk J, Olfson M. Psychiatric opinion and antipsychotic selection in the management of schizophrenia. Psychiatr Serv. 2008;59(5):561-565.
21. Hoadley J. Cost containment strategies for prescription drugs: assessing the evidence in the literature. Washington, DC:The Kaiser Family Foundation; March 2005.
22. Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA. 1990;263 (4):549-556.
23. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):iii-iv, 1-72.
24. O'Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2000;(2): CD000409.
25. Rosenheck RA, Leslie DL, Busch S, Rofman ES, Sernyak M. Rethinking antipsychotic formulary policy. Schizophr Bull. 2008;34(2):375-380.
26. Greenberg G, Rosenheck R. Department of Veterans Affairs National Mental Health Program Performance Monitoring System: fiscal year 2007 report. West Haven, CT: Northeast Program Evaluation Center; 2008.
27. Thaler RH, Sunstein CR. Nudge: Improving Decisions About Health, Wealth, and Happiness. New Haven: CT: Yale University Press; 2008.
28. Greenberg G, Rosenheck R. Department of Veterans Affairs National Mental Health Program Performance Monitoring System: fiscal year 2010 report. West Haven, CT: Northeast Program Evaluation Center; 2010.
29. Davis DA, Thomson MA, Oxman AD, et al. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA. 1995;274(9):700-705.
30. Benjamin D, Swartz M, Forman L. The impact of evidence-based education on prescribing in a psychiatry residency. J Psychiatr Pract. 2011;17(2):110-117.
31. van Eijk MEC, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomized trial of group versus individual academic detailing. BMJ. 2001; 322(7287):654-657.
32. Ray WA, Taylor JA, Meador KG, et al. Reducing antipsychotic drug use in nursing homes: a controlled trial of provider education. Arch Int Med. 1993;153(6):713-721.
33. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Eng J Med. 1992;327:168-173.
34. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
35. Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2008;69(suppl 1):18-31.
36. Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry. 2007; 164(1):174-175.
37. Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(5):532-535.
38. Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry. 2006;67(6):972-982.
39. Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker WW. Offlabel use of antipsychotic drugs. J Clin Psychopharmacol. 2000;20(6): 695-698.
40. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011;306(5):493-502.
41. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003; 23(1):15-20.
42. Miller BJ, Paschall III CB, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv. 2006;57(10):1482-1487.
43. Yu W, Ravelo A, Wagner TH, et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev. 2003;60 (3 suppl):146S-167S.
44. North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res. 2004;12(2):362-368.
45. Jerrell, JM, McIntyre RS, Black, GB. Economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor. Psychiatr Serv. 2012;63(3):202-204.